NCT06046534 (ERYTHRO) is a clinical trial of None (Observational study) in Systemic Lupus Erythematosus, sponsored by AstraZeneca.

Who is sponsoring NCT06046534?

NCT06046534 is sponsored by AstraZeneca.

What drugs are being tested in NCT06046534?

Interventions in NCT06046534: None (Observational study).

What condition does NCT06046534 study?

NCT06046534 studies Systemic Lupus Erythematosus.

Is NCT06046534 still recruiting?

NCT06046534 is currently completed. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT06046534: ERYTHRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.

Completed Last updated 13 May 2025

What this trial tests

trial testing None (Observational study) in Systemic Lupus Erythematosus in 46 participants. Completed in 10 June 2024.

Timeline

27 October 2023

Primary endpoint
10 June 2024

10 June 2024

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	46
Start date	27 October 2023
Primary completion	10 June 2024
Estimated completion	10 June 2024
Sites	15 locations across France, Italy, Greece, United Kingdom, Israel, Portugal, Spain

Drugs / interventions tested

None (Observational study)

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ERYTHRO study is a retrospective medical chart review study of patients in the AMANA and ATUc Early Access Programs (EAPs) across a number of countries, to assess anifrolumab usage and patient experience in treating SLE in a real-world setting. Since patient safety data are already collected and reported according to regulatory requirements through EAPs, this study will not collect safety data.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interferon Inhibition in SLE: From Bench to Bedside.
Deligeorgakis D, Skouvaklidou E, Adamichou C. · · 2024 · cited 3× · PMID 39193183 · DOI 10.31138/mjr.010324.iis
Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes.
Vital EM, Chasset F, Faria R, Carter LM, et al · · 2026 · PMID 41986078 · DOI 10.1136/lupus-2025-001704

Verify or expand the search:

Other trials of None (Observational study)

Trials testing the same drug.

NCT07346768 — Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients · not yet recruiting
NCT07141277 — GRANITE: Airsupra Effectiveness in the Real World · recruiting
NCT06222957 — The Effects of HER2 Receptor Signaling on Human Brown Fat Activity · recruiting
NCT06527872 — Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN · recruiting
NCT06607068 — Assessment of Taurine Concentration in Older Women With/Without Obesity And With/Without Type 2 Diabetes Mellitus · active not recruiting

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06046534 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06046534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing